AIM ImmunoTech Stock Surges 57% in After-Hours Trading

AIM ImmunoTech Inc. (AIM) stock surged 57.15% in after-hours trading on May 18, 2026, climbing to $0.3976 per share on the AMEX exchange. The biotech company saw exceptional trading volume of 465.7 million shares, roughly 127 times its average daily volume. This dramatic move reflects heightened investor interest in the immuno-pharma developer, which focuses on cancer therapeutics and viral disease treatments. AIM stock trades above its 50-day average of $0.589 but remains well below its 200-day average of $1.50.

AIM Stock Price Action and Trading Volume

AIM ImmunoTech stock opened at $0.2756 and reached a session high of $0.693 before settling at $0.3976 in after-hours trading. The $0.1446 gain represents one of the most active trading days for the micro-cap biotech stock. Volume exploded to 465.7 million shares, dwarfing the typical 3.7 million daily average.

The stock’s year-to-date performance remains deeply negative, down 64.6% from the start of 2026. However, the five-day gain of 35.14% and one-day surge suggest renewed speculative interest. The stock trades significantly below its 52-week high of $19.74, reflecting the company’s challenging operational environment.

AIM ImmunoTech’s Financial Position and Challenges

AIM ImmunoTech operates in the biotechnology sector with a market capitalization of just $1.36 million, making it a micro-cap stock. The company reported negative earnings per share of -$8.62, reflecting ongoing losses from research and development activities. Revenue per share stands at only $0.0286, indicating minimal commercial traction for its pipeline.

The company’s balance sheet shows significant stress. Working capital is negative at -$2.93 million, and the current ratio of 0.53 signals liquidity concerns. Track AIM on Meyka for real-time updates on this volatile biotech name. Debt-to-assets ratio of 0.85 indicates heavy leverage relative to asset base.

AIM Stock Rating and Investment Outlook

Meyka AI rates AIM ImmunoTech with a grade of B, suggesting a HOLD recommendation based on comprehensive analysis. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s price-to-sales ratio of 9.68 appears elevated given minimal revenue generation.

Meyka AI’s forecast model projects AIM stock could reach $3.27 within one year, implying 722% upside from current levels. However, these grades are not guaranteed and we are not financial advisors. The five-year forecast of $8.54 suggests significant recovery potential if the company achieves clinical or commercial milestones.

Biotech Pipeline and Therapeutic Focus

AIM ImmunoTech develops immunotherapeutics targeting multiple disease areas. Its flagship product Ampligen (rintatolimod) is approved for chronic fatigue syndrome and is being studied for pancreatic, lung, and breast cancers. Alferon N Injection treats genital warts and represents the company’s established revenue source.

The company is also exploring Ampligen for viral diseases including HIV, Hepatitis B, and COVID-19 treatments. With only 21 full-time employees, AIM operates as a lean development-stage biotech. Next earnings announcement is scheduled for August 13, 2026, which could provide clarity on clinical progress and cash runway.

Final Thoughts

AIM ImmunoTech stock’s 57% surge reflects speculative trading rather than fundamental catalysts, given the company’s minimal revenue and negative earnings. The massive volume spike suggests retail interest in the micro-cap biotech name. Investors should monitor the August earnings report and any clinical trial updates for Ampligen. The stock remains highly volatile and suitable only for risk-tolerant traders with conviction in the company’s therapeutic pipeline.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.